Morgan Stanley Downgrades Infinity Pharmaceutical (INFI) to Equalweight

William Blair Downgrades Infinity Pharmaceutical (INFI) to Market Perform

William Blair downgraded Infinity Pharmaceutical (NASDAQ: INFI) from Outperform to Market Perform with a price target of $2.00 (from $20.00).

For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.

Shares of Infinity Pharmaceutical closed at $1.36 yesterday.

FBR Capital Downgrades Infinity Pharmaceutical (INFI) to Market Perform

FBR Capital downgraded Infinity Pharmaceutical (NASDAQ: INFI) from Outperform to Market Perform with a price target of $2.00 (from $15.00).

Analyst Christopher James commented, "We are downgrading our rating of Infinity Pharmaceuticals to Market Perform and lowering our price target to $2 from $15 following disappointing data from Infinity's Phase II DYNAMO study with duvelisib in patients with... More

Wedbush Upgrades Infinity Pharmaceutical (INFI) to Neutral

Wedbush upgraded Infinity Pharmaceutical (NASDAQ: INFI) from Underperform to Neutral with a price target of $1.25.

For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.

Shares of Infinity Pharmaceutical closed at $4.41 yesterday.

JPMorgan Downgrades Infinity Pharmaceutical (INFI) to Neutral

JPMorgan downgraded Infinity Pharmaceutical (NASDAQ: INFI) from Overweight to Neutral.

For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.

Shares of Infinity Pharmaceutical closed at $4.41 yesterday.

Infinity Pharma (INFI) Announces Duvelisib Phase 2 Met Primary Endpoint in r/r NHL; Will Undertake Restructuring

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that DYNAMO, a registration-focused Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with refractory indolent non-Hodgkin lymphoma (iNHL) met its primary endpoint of overall response rate. In the study, duvelisib demonstrated an overall response rate (ORR) of 46 percent, all of which were partial responses, among 129 patients with iNHL. The majority of reported side effects were reversible and clinically manageable.

"While the DYNAMO study met its primary endpoint, we... More